http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002501492-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 1998-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2002501492-A |
| titleOfInvention | Quino- and quinazolines as CRF antagonists |
| abstract | SUMMARY OF THE INVENTION The present invention relates to a compound of the formula (I) comprising a stereoisomer and a pharmaceutically acceptable acid addition salt form having CRF receptor antagonist properties, wherein R 1 is C 1-6 alkyl. , NR 6 R 7 , OR 6 or SR 7 ; R 2 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy or C 1-6 alkylthio; R 3 is Ar 1 or Het 1 R 4 and R 5 are each independently of hydrogen, halo, C 1-6 alkyl, C 1-6 alkyloxy, trifluoromethyl, cyano, nitro, amino and mono- or di (C 1-6 alkyl) amino; R 6 is hydrogen, C 1-6 alkyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfoxy or C 1-6 alkylthio; R 7 is hydrogen, C 1-8 alkyl, mono - or di (C 3-6 cycloalkyl) methyl, C 3-6 cycloalkyl, C 3-6 Al Alkenyl, hydroxy C 1-6 alkyl, C 1-6 alkylcarbonyloxy C 1-6 alkyl or C 1-6 alkyloxy C 1-6 alkyl; R 6 is C 1-8 alkyl, mono- - or di ( C 3-6 cycloalkyl) methyl, Ar 2 CH 2 , C 1-6 alkyloxy C 1-6 alkyl, hydroxy C 1-6 alkyl, C 3-6 alkenyl, thienylmethyl, furanylmethyl, C 1-6 alkylthio C 1-6 alkyl, mono- or di (C 1-6 alkyl) amino C 1-6 alkyl, di (C 1-6 alkyl) amino, C 1-6 alkylcarbonyl C 1-6 alkyl; 6 and R 7 may be substituted optionally together with the nitrogen atom to which they are attached by C 1-6 alkyl or C 1-6 alkyloxy C 1-6 alkyl pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl May be formed; and Ar 1 and Ar 2 are each optionally be phenyl optionally substituted; and Het 1 is pyridinyl optionally substituted by case, of the compound; thereof as an active ingredient Pharmaceutical compositions containing such compounds; methods of treating diseases associated with hypersecretion of CRF, such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010536829-A |
| priorityDate | 1997-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.